|
1
|
Travis WD, Rush W, Flieder DB, Falk R,
Fleming MV, Gal AA and Koss MN: Survival analysis of 200 pulmonary
neuroendocrine tumors with clarification of criteria for atypical
carcinoid and its separation from typical carcinoid. Am J Surg
Pathol. 22:934–944. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Skuladottir H, Hirsch FR, Hansen HH and
Olsen JH: Pulmonary neuroendocrine tumors: Incidence and prognosis
of histological subtypes. A population-based study in Denmark. Lung
Cancer. 37:127–135. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cooper WA, Thourani VH, Gal AA, Lee RB,
Mansour KA and Miller JI: The surgical spectrum of pulmonary
neuroendocrine neoplasms. Chest. 119:14–18. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Papadimitrakopoulou V: Development of
PI3K/AKT/mTOR pathway inhibitors and their application in
personalized therapy for non-small-cell lung cancer. J Thorac
Oncol. 7:1315–1326. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Brown EJ, Albers MW, Shin TB, Ichikawa K,
Keith CT, Lane WS and Schreiber SL: A mammalian protein targeted by
G1-arresting rapamycin-receptor complex. Nature. 369:756–758. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Capdevila J, Salazar R, Halperín I, Abad A
and Yao JC: Innovations therapy: Mammalian target of rapamycin
(mTOR) inhibitors for the treatment of neuroendocrine tumors.
Cancer Metastasis Rev. 30 Suppl 1:27–34. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hay N: The Akt-mTOR tango and its
relevance to cancer. Cancer Cell. 8:179–183. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rosner M, Hanneder M, Siegel N, Valli A,
Fuchs C and Hengstschlager M: The mTOR pathway and its role in
human genetic diseases. Mutat Res. 659:284–292. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sato T, Umetsu A and Tamanoi F:
Characterization of the Rheb-mTOR signaling pathway in mammalian
cells: Constitutive active mutants of Rheb and mTOR. Methods
Enzymol. 438:307–320. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chiang GG and Abraham RT: Targeting the
mTOR signaling network in cancer. Trends Mol Med. 13:433–442. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yao JC, Phan AT, Chang DZ, Wolff RA, Hess
K, Gupta S, Jacobs C, Mares JE, Landgraf AN, Rashid A and
Meric-Bernstam F: Efficacy of RAD001 (everolimus) and octreotide
LAR in advanced low- to intermediate-grade neuroendocrine tumors:
Results of a phase II study. J Clin Oncol. 26:4311–4318. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yao JC, Shah MH, Ito T, Bohas CL, Wolin
EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG,
et al: Everolimus for advanced pancreatic neuroendocrine tumors. N
Engl J Med. 364:514–523. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Guertin DA and Sabatini DM: Defining the
role of mTOR in cancer. Cancer Cell. 12:9–22. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Molinolo AA, Hewitt SM, Amornphimoltham P,
Keelawat S, Rangdaeng S, García A Meneses, Raimondi AR, Jufe R,
Itoiz M, Gao Y, et al: Dissecting the Akt/mammalian target of
rapamycin signaling network: Emerging results from the head and
neck cancer tissue array initiative. Clin Cancer Res. 13:4964–4973.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Inoki K and Guan KL: Tuberous sclerosis
complex, implication from a rare genetic disease to common cancer
treatment. Hum Mol Genet. 18(R1): R94–R100. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Reinke A, Chen JC, Aronova S and Powers T:
Caffeine targets TOR complex I and provides evidence for a
regulatory link between the FRB and kinase domains of Tor1p. J Biol
Chem. 281:31616–31626. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Inoki K, Corradetti MN and Guan KL:
Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet.
37:19–24. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Young J and Povey S: The genetic basis of
tuberous sclerosis. Mol Med Today. 4:313–319. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Carsillo T, Astrinidis A and Henske EP:
Mutations in the tuberous sclerosis complex gene TSC2 are a cause
of sporadic pulmonary lymphangioleiomyomatosis. Proc Natl Acad Sci
USA. 97:pp. 6085–6090. 2000; View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Voortman J, Lee JH, Killian JK, Suuriniemi
M, Wang Y, Lucchi M, Smith WJ, Meltzer P, Wang Y and Giaccone G:
Array comparative genomic hybridization-based characterization of
genetic alterations in pulmonary neuroendocrine tumors. Proc Natl
Acad Sci USA. 107:pp. 13040–13045. 2010; View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dong M and Yao JC: mTOR inhibition, a
potential novel approach for bronchial carcinoids. Endocr Relat
Cancer. 18:C15–C18. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gagliano T, Bellio M, Gentilin E, Molè D,
Tagliati F, Schiavon M, Cavallesco NG, Andriolo LG, Ambrosio MR,
Rea F, et al: mTOR, p70S6K, AKT, and ERK1/2 levels predict
sensitivity to mTOR and PI3K/mTOR inhibitors in human bronchial
carcinoids. Endocr Relat Cancer. 20:463–475. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Travis WD, Brambilla E, Müller-Hermelink
HK and Harris CC: World HealthOrganization Classification of
TumoursPathology and Genetics of Tumours of the Lung, Pleura,
Thymus and Heart. IARC IARC Press; Lyon: 2004
|
|
24
|
Dabora SL, Jozwiak S, Franz DN, Roberts
PS, Nieto A, Chung J, Choy YS, Reeve MP, Thiele E, Egelhoff JC, et
al: Mutational analysis in a cohort of 224 tuberous sclerosis
patients indicates increased severity of TSC2, compared with TSC1,
disease in multiple organs. Am J Hum Genet. 68:64–80. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Anagnostou VK, Bepler G, Syrigos KN,
Tanoue L, Gettinger S, Homer RJ, Boffa D, Detterbeck F and Rimm DL:
High expression of mammalian target of rapamycin is associated with
better outcome for patients with early stage lung adenocarcinoma.
Clin Cancer Res. 15:4157–4164. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Oh MH, Lee HJ, Yoo SB, Xu X, Choi JS, Kim
YH, Lee SY, Lee CT, Jheon S and Chung JH: Clinicopathological
correlations of mTOR and pAkt expression in non-small cell lung
cancer. Virchows Arch. 460:601–609. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Righi L, Volante M, Rapa I, Tavaglione V,
Inzani F, Pelosi G and Papotti M: Mammalian target of rapamycin
signaling activation patterns in neuroendocrine tumors of the lung.
Endocr Relat Cancer. 17:977–987. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Walch AK, Zitzelsberger HF, Aubele MM,
Mattis AE, Bauchinger M, Candidus S, Präuer HW, Werner M and Höfler
H: Typical and atypical carcinoid tumors of the lung are
characterized by 11q deletions as detected by comparative genomic
hybridization. Am J Pathol. 153:1089–1098. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ullmann R, Schwendel A, Klemen H, Wolf G,
Petersen I and Popper HH: Unbalanced chromosomal aberrations in
neuroendocrine lung tumors as detected by comparative genomic
hybridization. Hum Pathol. 29:1145–1149. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhao J, de Krijger RR, Meier D, Speel EJ,
Saremaslani P, Muletta-Feurer S, Matter C, Roth J, Heitz PU and
Komminoth P: Genomic alterations in well-differentiated
gastrointestinal and bronchial neuroendocrine tumors (carcinoids):
Marked differences indicating diversity in molecular pathogenesis.
Am J Pathol. 157:1431–1438. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ullmann R, Petzmann S, Klemen H, Fraire
AE, Hasleton P and Popper HH: The position of pulmonary carcinoids
within the spectrum of neuroendocrine tumors of the lung and other
tissues. Genes Chromosomes Cancer. 34:78–85. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Warth A, Herpel E, Krysa S, Hoffmann H,
Schnabel PA, Schirmacher P, Mechtersheimer G and Bläker H:
Chromosomal instability is more frequent in metastasized than in
non-metastasized pulmonary carcinoids but is not a reliable
predictor of metastatic potential. Exp Mol Med. 41:349–353. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Katoh Y and Katoh M: Comparative
integromics on Angiopoietin family members. Int J Mol Med.
17:1145–1149. 2006.PubMed/NCBI
|
|
34
|
Rosner M, Freilinger A, Lubec G and
Hengstschläger M: The tuberous sclerosis genes, TSC1 and TSC2,
trigger different gene expression responses. Int J Oncol.
27:1411–1424. 2005.PubMed/NCBI
|
|
35
|
Pavel ME, Hainsworth JD, Baudin E, Peeters
M, Hörsch D, Winkler RE, Klimovsky J, Lebwohl D, Jehl V, Wolin EM,
et al: Everolimus plus octreotide long-acting repeatable for the
treatment of advanced neuroendocrine tumours associated with
carcinoid syndrome (RADIANT-2): A randomised, placebo-controlled,
phase 3 study. Lancet. 378:2005–2012. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Fazio N, Granberg D, Grossman A, Saletan
S, Klimovsky J, Panneerselvam A and Wolin EM: Everolimus plus
octreotide long-acting repeatable in patients with advanced lung
neuroendocrine tumors: Analysis of the phase 3, randomized,
placebo-controlled RADIANT-2 study. Chest. 143:955–962. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zatelli MC, Minoia M, Martini C, Tagliati
F, Ambrosio MR, Schiavon M, Buratto M, Calabrese F, Gentilin E,
Cavallesco G, et al: Everolimus as a new potential
antiproliferative agent in aggressive human bronchial carcinoids.
Endocr Relat Cancer. 17:719–729. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Iyer G, Hanrahan AJ, Milowsky MI,
Al-Ahmadie H, Scott SN, Janakiraman M, Pirun M, Sander C, Socci ND,
Ostrovnaya I, et al: Genome sequencing identifies a basis for
everolimus sensitivity. Science. 338:2212012. View Article : Google Scholar : PubMed/NCBI
|
